bpc 157 strate labs BPC-157 Canada BPC-157 Europe - RUO Research

This peptide was originally developed by Professor Frank Ng at Monash University in Australia during the 1990s as a potential anti-obesity treatment

Fulminant Wilson disease is characterized by only modest increases in aminotransferase levels and a low or normal ALP level despite clinical evidence of liver failure, such as a prolonged prothrombin time and high bilirubin concentration

This could be 1000 mcg daily or less, based on the patients needs

If the immune system attacks, implantation fails

In wound healing studies, rats treated with TB-500 showed 42 percent increased re-epithelialization over controls at four days and up to 61 percent at seven days